Ensysce Biosciences Company Insiders
| ENSC Stock | USD 0.86 0.03 3.37% |
Ensysce Biosciences employs about 7 people. The company is managed by 7 executives with a total tenure of roughly 17 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Evaluation of Ensysce Biosciences' management performance can provide insight into the firm performance.
Ensysce Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (1.0979) % which means that it has lost $1.0979 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9439) %, meaning that it created substantial loss on money invested by shareholders. Ensysce Biosciences' management efficiency ratios could be used to measure how well Ensysce Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of January 26, 2026, Return On Tangible Assets is expected to decline to -1.35. The current year's Return On Capital Employed is expected to grow to -1.7. The current year's Non Currrent Assets Other is expected to grow to about 305 K, whereas Total Assets are forecasted to decline to about 4.8 M.The current year's Common Stock Shares Outstanding is expected to grow to about 1.6 M, whereas Net Loss is forecasted to decline to (7.5 M). Roughly 89.78 percent of Ensysce Biosciences outstanding shares are held by general public with 0.29 (percent) owned by insiders and only 9.93 % by other corporate entities.
Shares in Circulation | First Issued 2017-12-31 | Previous Quarter 2.2 M | Current Value 2.9 M | Avarage Shares Outstanding 2.9 M | Quarterly Volatility 2.6 M |
Ensysce Biosciences Workforce Comparison
Ensysce Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 130. Ensysce Biosciences holds roughly 7.0 in number of employees claiming about 5% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.44) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (7.59) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $7.59. Ensysce Biosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ensysce Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ensysce Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ensysce Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Benton Andrew over a month ago Acquisition by Benton Andrew of 65850 shares of Ensysce Biosciences at 3.35 subject to Rule 16b-3 | ||
Lynn Kirkpatrick over two months ago Acquisition by Lynn Kirkpatrick of 6585 shares of Ensysce Biosciences at 2.59 subject to Rule 16b-3 | ||
Birkett Kevin Geoffrey over three months ago Acquisition by Birkett Kevin Geoffrey of 50000 shares of Ensysce Biosciences at 1.4 subject to Rule 16b-3 | ||
Chang William H over six months ago Insider Trading | ||
Lynn Kirkpatrick over six months ago Acquisition by Lynn Kirkpatrick of 263400 shares of Ensysce Biosciences at 3.19 subject to Rule 16b-3 | ||
Martin Steven Robert over six months ago Acquisition by Martin Steven Robert of 65850 shares of Ensysce Biosciences at 3.35 subject to Rule 16b-3 | ||
Carrera Eric over six months ago Disposition of 8330 shares by Carrera Eric of Ensysce Biosciences subject to Rule 16b-3 | ||
Gower Bob G over six months ago Acquisition by Gower Bob G of 7919026 shares of Ensysce Biosciences subject to Rule 16b-3 |
Ensysce Biosciences Notable Stakeholders
An Ensysce Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ensysce Biosciences often face trade-offs trying to please all of them. Ensysce Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ensysce Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Lynn Kirkpatrick | CEO President | Profile | |
| William Schmidt | Chairman Officer | Profile | |
| David CPA | Secretary CFO | Profile | |
| MSE MBA | Chief Officer | Profile | |
| Geoffrey Birkett | Chief Officer | Profile | |
| Jeffrey Millard | Chief Officer | Profile | |
| Linda Pestano | Chief Officer | Profile |
About Ensysce Biosciences Management Performance
The success or failure of an entity such as Ensysce Biosciences often depends on how effective the management is. Ensysce Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ensysce management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ensysce management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.28) | (1.35) | |
| Return On Capital Employed | (1.79) | (1.70) | |
| Return On Assets | (1.28) | (1.35) | |
| Return On Equity | (1.94) | (1.84) |
Please note, the presentation of Ensysce Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ensysce Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ensysce Biosciences' management manipulating its earnings.
Ensysce Biosciences Workforce Analysis
Traditionally, organizations such as Ensysce Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ensysce Biosciences within its industry.Ensysce Biosciences Manpower Efficiency
Return on Ensysce Biosciences Manpower
| Revenue Per Employee | 744.3K | |
| Revenue Per Executive | 744.3K | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 1.1M | |
| Working Capital Per Employee | 448.2K | |
| Working Capital Per Executive | 448.2K |
Complementary Tools for Ensysce Stock analysis
When running Ensysce Biosciences' price analysis, check to measure Ensysce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ensysce Biosciences is operating at the current time. Most of Ensysce Biosciences' value examination focuses on studying past and present price action to predict the probability of Ensysce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ensysce Biosciences' price. Additionally, you may evaluate how the addition of Ensysce Biosciences to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |